This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Valeant Pharmaceuticals CEO Discusses Q3 2010 Results - Earnings Call Transcript

Valeant Pharmaceuticals International, Inc. ( VRX)

Q3 2010 Earnings Call

November 4, 2010 8:00 AM EST

Executives

Laurie Little – IR

Mike Pearson – CEO

Rajiv De Silva – President and COO, Specialty Pharmaceuticals.

Peggy Mulligan – CFO

Analysts

Randall Stanicky – Goldman Sachs

Gregg Gilbert – Bank of America Merrill Lynch

Marc Goodman – UBS

Corey Davis – Jefferies

Douglas Miehm – RBC Capital Markets

Annabel Samimy – Stifel Nicolaus

Lennox Gibbs – TD Securities

Michael Tong – Wells Fargo

Hari Sambasivam – National Bank Financial

Graham Tanaka – Tanaka Capital

Juan Sanchez – Ladenburg

Presentation

Operator

Good morning. My name is Amanda and I will be your conference operator today. At this time, I would like to welcome everyone to the Valeant third quarter 2010 earnings conference call.

All lines have been placed on mute to prevent any background noise. After the speakers' remarks there will be a question-and-answer session. (Operator Instructions). Thank you.

Ms. Laurie Little, you may begin your conference.

Laurie Little

Good morning, and welcome, everyone to Valeant's third quarter 2010 financial results conference call. Joining us on the call today are Mike Pearson, Chief Executive Officer; Peggy Mulligan, Chief Financial Officer; and Rajiv De Silva, President and Chief Operating Officer of Specialty Pharmaceuticals.

In addition to this live webcast, a copy of today's slide presentation can be found on our website under the Investor Relations section within the webcast event details.

Before we begin, please turn your attention to the slide containing our cautionary statement regarding forward-looking statements. Certain statements made in this presentation and other statements made during this call and the Q&A session afterwards may constitute forward-looking statements.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 18,100.49 -62.50 -0.34%
S&P 500 2,115.99 -7.49 -0.35%
NASDAQ 5,090.5940 -15.9990 -0.31%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs